Clinical Update

Company details clinical development plan for CG53135 and CR002

Published in Clinical Trials Week, November 29th, 2004

CuraGen Corp. (CRGN) announced progress with their pipeline of protein, antibody, and small-molecule therapeutics highlighted by the transitioning of CG53135 into phase II for the prevention of oral mucositis (OM) in cancer patients undergoing bone marrow transplantation (BMT).

The company also announced that CR002, a fully human monoclonal antibody, is being developed for the treatment of IgA nephropathy and will begin a phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy male volunteers.

"We are very pleased to transition CG53135 into phase II and bring CR002 into a phase I program. CuraGen...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Clinical Trials Week

Source: Clinical Trials Week (2004-11-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry